drug
zolucatetide
Phase 2updated 6mo agoby Parabilis Medicines
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
News(4)
- Once undruggable, the Wnt/B-catenin pathway shows increasing promiseEarly-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types.biospace · 19d ago
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…biospace · 3mo ago
- Parabilis sets a record with a $670M biotech IPOThe largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.biopharma_dive · 5mo ago
- Fierce Biotech Fundraising Tracker '26: China's Eli Radiopharma raises $60M; Neurosterix notches $105MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 11mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that